A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 6
- 主要终点
- Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review
研究概览
简要总结
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group Performance Status of 0 or 1
- •Histologically confirmed, resectable Stage III-IVA SCCHN
- •Eligible candidate for R0 resection with curative intent at the time of screening
- •HPV-negative test for oropharyngeal carcinoma, as determined locally by p16 immunohistochemistry (IHC), in situ hybridization, or polymerase chain reaction-based assay
- •Measurable disease (at least one target lesion), as assessed according to RECIST v1.1
- •PD-L1 expression, defined as a combined positive score (CPS) >= 1
- •Adequate hematologic and end-organ function
- •Negative HIV test with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count >= 200/μL, and have an undetectable viral load.
- •Negative hepatitis B surface antigen (HBsAg) test at screening
- •Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: Negative total hepatitis B core antibody (HBcAb), Positive total hepatitis B core antibody (HBcAb) followed by a negative quantitative hepatitis B virus (HBV) DNA.
排除标准
- •HPV-positive oropharyngeal cancer, as determined locally by p16 IHC, in situ hybridization, or by polymerase chain reactions-based assay
- •Distantly metastasized SCCHN
- •Any prior therapy for SCCHN, including immunotherapy, chemotherapy, or RT
- •Prior treatment with any of the protocol-specified study treatments
- •Treatment with investigational therapy within 42 days prior to initiation of study treatment
- •Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
- •Prior allogeneic stem cell or solid organ transplantation
- •Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment
- •Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment
- •Active or history of autoimmune disease or immune deficiency
- •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT scan)
- •History of malignancy other than SCCHN within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5 -year OS rate>90%)
- •Active tuberculosis
- •Severe infection within 4 weeks prior to initiation of study treatment
- •Treatment with therapeutic or prophylactic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment
- •Significant cardiovascular disease such a New York Heart Association cardiac disease (Class II or greater), myocardial infarction or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhytmia, or unstable angina
- •Major surgical procedure, other than for diagnosis, within 4 weeks prior to study initiation of study treatment, or anticipation of need for a major surgical procedure other than tumor resection, during the study
- •Any of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of investigational drug, may affect the interpretation of the results, impair the ability of the patient to participate in the study, or renders the patient at high risk form treatment complications
- •History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins
- •Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies
- •Known allergy or hypersensitivity to any of the study drugs or their excipients
- •Known intolerance to any of the drugs required for premedication
- •Pregnancy or breastfeeding, or intention of becoming pregnant during the study
- •Eligible only for the control arm
- •Active EBV infection or known or suspected chronic EBV infection at screening
- •Specific Exclusion Criteria for Atezo+Tira+CP:
- •Known severe allergy or hypersensitivity to placlitaxel, platinum or platinum-containing compounds
- •Known history of severe hypersensitivity to products containing Cremophor EL
- •Creatinine clearance <45m./min (Calculated using the Cockcroft-Gault formula)
研究组 & 干预措施
Atezo + Tira
Participants in the atezolizumab plus tiragolumab arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
干预措施: Atezolizumab (Drug)
Atezo + Tira
Participants in the atezolizumab plus tiragolumab arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
干预措施: Tiragolumab (Drug)
Atezo + Tira + CP
Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
干预措施: Atezolizumab (Drug)
Atezo + Tira + CP
Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
干预措施: Tiragolumab (Drug)
Atezo + Tira + CP
Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
干预措施: Carboplatin (Drug)
Atezo + Tira + CP
Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review
时间窗: At the time of surgery (Week 7 ± 1 week)
pCR was defined as the absence of any viable primary tumor at time of surgical resection, as determined by local pathologic review. The pCR rate was defined as the percentage of participants who achieved a pCR. pCR rate was calculated for each arm, along with the 95% confidence interval (CI) estimated using the Clopper-Pearson method and the 95% CI for difference in rates was estimated using the Wald method with continuity correction. Participants with missing or no pathologic response assessment were classified as non-responders. Percentages have been rounded off to the nearest whole number.
次要结局
- Pathologic Response Rate (pRR) as Determined by Local Pathologic Review(At the time of surgery (Week 7 ± 1 week))
- Event-Free Survival (EFS)(From randomization to PD disease recurrence or death (Up to 9.2 months))
- Relapse-Free Survival (RFS)(From surgery (scheduled at Week 7 ± 1 week) to first documented disease recurrence or death (up to 7.6 months))
- Overall Survival (OS)(From randomization to death from any cause or last known to be alive (Up to 9.2 months))
- Objective Response Rate (ORR)(Prior to surgery (up to Week 6))
- Landmark EFS Rate(3 Months, 6 Months, and 1 Year)
- Landmark RFS Rate(3 Months, 6 Months, and 1 Year)
- Landmark OS Rate(3 Months, 6 Months, and 1 Year)
- Number of Participants With Adverse Events (AEs)(From initiation of study treatment up to 135 days after the final dose of study treatment (up to 5.1 months))
- Number of Participants With Immune-Related AEs Grade >=3(Up to 12 weeks)
- Rate of Delayed Surgery Due to Treatment-Related AEs(Delay up to week after the planned time of surgery (scheduled at Week 7 ± 1 week) up to 2 weeks (up to Week 9))
- Duration of Delayed Surgery Due to Treatment-Related AEs(Delay up to week after the planned time of surgery (scheduled at Week 7 ± 1 week) up to 2 weeks (up to Week 9))
- Rate of Surgical Complications as Assessed According to the Clavien-Dindo Surgical Classification(From Surgery (Week 7 ± 1 week) up to 5.1 months)